Celltrion presents new two-year data for subcutaneous infliximab (CT-P13 SC) in inflammatory bowel disease (IBD) at the 19th ECCO Congress
Business Wire India Results of the two-year LIBERTY studies demonstrate that CT-P13 SC provides long-term clinical benefits and safety, with the convenience of subcutaneous (SC) administration, in the treatment of…